Monitor for potential improvements in financial governance and capital allocation strategy given Goldan's experience with commercial-stage biotechs and capital markets. No immediate trading catalyst, but could support long-term execution.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 7 $4.81entry
- T+1 · 7mo ago +1.25%α −1.29% · $4.87
- T+5 · 7mo ago +7.90%α +2.57% · $5.19
- T+20 · 7mo ago +23.70%α +13.92% · $5.95
- T+60 · 5mo ago +33.06%α +19.79% · $6.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Abeona Therapeutics appointed Keith A. Goldan to its Board of Directors and as Chair of the Audit Committee, citing his two decades of financial leadership experience in biotech. The move strengthens governance as the company advances its commercial-stage gene therapy operations.
Key Facts
- Keith A. Goldan appointed to Board of Directors effective April 1, 2026
- Goldan also named Chair of the Audit Committee
- Board expanded from nine to ten members
- Goldan is independent under Nasdaq rules
- Compensation includes $50,000 annual cash fee and $150,000 sign-on equity grant
Financial Impact
Minimal immediate financial impact. $150,000 one-time equity grant and $50,000 annual cash fee represent negligible costs for a company with $272M market cap.
Risk Factors
- New director appointments do not guarantee improved performance
- Company continues to face commercialization risks with ZEVASKYN as noted in forward-looking statements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-015451 |
| Exhibit: ex99-1.htm | 0001493152-26-015451 |
| Document: 0001493152-26-015451-index-headers.html | 0001493152-26-015451 |
| Document: 0001493152-26-015451-index.html | 0001493152-26-015451 |
| Document: 0001493152-26-015451.txt | 0001493152-26-015451 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $2.59 Now $2.60 +0.39% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers